Skip to main content

Table 1 Enrollment per study site in the survey and the prevention study

From: Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

Country

Study site ID

Survey study

Prevention study

All dogs

A. vasorum positive

Total

n

n

%

n

%

Denmark

DA

50

19

38.0

31

5.0

DB

92

5

5.4

18

2.9

DD

15

0

0

9

1.4

DE

18

1

5.6

23

3.7

DF

23

2

8.7

29

4.7

DG

44

2

4.5

25

4.0

DH

1

0

0

0

0

DI

38

2

5.3

9

1.4

DJ

11

0

0

15

2.4

DK

10

5

50.0

9

1.4

DL

25

9

36.0

38

6.1

DM

52

1

1.9

37

5.9

DN

87

3

3.4

21

3.4

DO

42

7

16.7

13

2.1

DP

78

5

6.4

12

1.9

DR

22

6

27.3

30

4.8

Italy

IA

83

5

6.0

23

3.7

IB

60

2

3.3

14

2.3

IC

82

5

6.1

20

3.2

ID

58

4

6.9

19

3.1

IE

82

12

14.6

25

4.0

IF

71

21

29.6

26

4.2

IG

79

15

19.0

38

6.1

IH

90

3

3.3

18

2.9

II

73

0

0

14

2.3

IJ

72

8

11.1

25

4.0

IK

49

9

18.4

17

2.7

IL

67

7

10.4

14

2.3

IN

82

29

35.4

30

4.8

IO

67

11

16.4

20

3.2

Total

 

1623

198

12.2

622

100

  1. Notes: For the survey study the total number of tested dogs and the number and percent of Angiostrongylus vasorum positive dogs is shown for each study site. For the prevention study the number and percent of all enrolled animals is provided per study site. Site DH withdrew from the studies